Angion Biomedica Corp:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Angion Biomedica Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3031
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Angion Biomedica Corp (Angion) is a clinical-stage organ restoration biopharmaceutical company that discovers and develops novel treatments for the treatment of renal and chronic organ injury and disease. The company’s pipeline products include BB3, ANG-3070, ANG-3586, ANG-4201, TBD and ANG-4102. Its BB3 is a HGF-like small molecule compound, which is used to treat various indications such as acute kidney injury, renal transplantation and delayed graft function. Angion’s ANG-3070, is a fibrokinase inhibitor which is being developed to treat chronic renal disease. It also conducts preclinical development programs in chronic kidney disease including diabetic nephropathy and polycystic kidney disease. The company operates through its research and development facility located in New York. Angion is headquartered in Uniondale, New York, the US.

Angion Biomedica Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Angion Biomedica Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Angion Biomedica Enters into Licensing Agreement with ElexoPharm 10
Angion Biomedica Enters into Licensing Agreement with Ohr Cosmetics for ANG-3522 11
Equity Offering 12
Angion Biomedica Withdraws IPO 12
Angion Biomedica Corp – Key Competitors 14
Angion Biomedica Corp – Key Employees 15
Angion Biomedica Corp – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Sep 07, 2017: Angion Biomedica Expands Personnel with New Director of Discovery and Medicinal Chemistry, and Director of Clinical Operations 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Key Facts 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Angion Biomedica Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Angion Biomedica Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Angion Biomedica Enters into Licensing Agreement with ElexoPharm 10
Angion Biomedica Enters into Licensing Agreement with Ohr Cosmetics for ANG-3522 11
Angion Biomedica Withdraws IPO 12
Angion Biomedica Corp, Key Competitors 14
Angion Biomedica Corp, Key Employees 15

List of Figures
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Angion Biomedica Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CareDx Inc (CDNA):企業の財務・戦略的SWOT分析
    Summary CareDx Inc (CareDx) formerly XDx Inc, is a molecular diagnostics company focused on the discovery, development, and commercialization of diagnostic solutions for transplant patients. The company offers products which include AlloMap, a noninvasive blood test used by clinicians to monitor and …
  • Ohr Pharmaceutical Inc (OHRP):製薬・医療:M&Aディール及び事業提携情報
    Summary Ohr Pharmaceutical Inc (Ohr), formerly BBM Holdings Inc, is a pharmaceutical company that develops novel therapies for ophthalmic diseases. The company offers products such as squalamine lactate ophthalmic solution and SKS sustained release technology products. Its squalamine lactate ophthal …
  • WABCO Holdings Inc.:企業の戦略・SWOT・財務情報
    WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • TYI 2011 Ltd:企業の戦略的SWOT分析
    TYI 2011 Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • GenomicTree Co Ltd (228760):企業の製品パイプライン分析
    Summary GenomicTree Co Ltd (GenomicTree) is a medical device company that develops and commercializes diagnostic products for the screening and diagnosis of cancer. The company also provides non-invasive cancer molecular diagnostic product. Its products are used in the detection of colorectal, lung …
  • Petroleos de Venezuela SA-エネルギー分野:企業M&A・提携分析
    Summary Petroleos de Venezuela SA (PDVSA) is a state-owned oil and gas company. It plans, coordinates, supervises, and controls the activities in the entire oil and gas value chain. The company explores for and develops oil and other hydrocarbons; refines, trades, and supplies that in domestic and o …
  • Ecobliss Holding BV:企業の戦略・SWOT・財務情報
    Ecobliss Holding BV - Strategy, SWOT and Corporate Finance Report Summary Ecobliss Holding BV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Stealth BioTherapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Stealth BioTherapeutics Inc (Stealth), formerly Stealth Peptides Inc is a clinical stage biopharmaceutical company that develops therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. The company offers elamipretide, a mitoch …
  • Amec Foster Wheeler plc (formerly AMEC plc):戦略・SWOT・企業財務分析
    Amec Foster Wheeler plc (formerly AMEC plc) - Strategy, SWOT and Corporate Finance Report Summary Amec Foster Wheeler plc (formerly AMEC plc) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • ZyGEM NZ Ltd:医療機器:M&Aディール及び事業提携情報
    Summary ZyGEM NZ Ltd (ZyGEM), a subsidiary of MicroGEM International PLC is a drug development company that develops and technologies for life science, agricultural and horticultural industries. The company produces DNA extraction products, and enzymes used in diagnostics, molecular biology and indu …
  • TransAtlantic Petroleum Ltd (TAT):企業の財務・戦略的SWOT分析
    TransAtlantic Petroleum Ltd (TAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Adocia SAS (ADOC):企業の財務・戦略的SWOT分析
    Summary Adocia SAS (Adocia) is a biotechnology comapny involved in the develoment of therapeutic proteins. The company provides products such as formulation of PDGF-BB for the treatment of diabetic foot ulcers. Adocia's novel insulin formulations is used for the treatment of diabetes and BioChaperon …
  • Oragenics Inc (OGEN)-製薬・医療分野:企業M&A・提携分析
    Summary Oragenics Inc (Oragenics) is a biopharmaceutical company that focuses on the development and commercialization of novel antibiotics against infectious disease and develops treatments for oral mucositis. The company develops a new class of potent gram-positive antibiotics which are called Lan …
  • Marquette Capital Partners LLC:企業の戦略・SWOT・財務分析
    Marquette Capital Partners LLC - Strategy, SWOT and Corporate Finance Report Summary Marquette Capital Partners LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Eu Yan Sang International Ltd:企業の戦略的SWOT分析
    Eu Yan Sang International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Diagnostica Stago SAS:企業の戦略的SWOT分析
    Diagnostica Stago SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Apple Inc:企業のM&A・事業提携・投資動向
    Apple Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Apple Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Unicharm Corporation (8113):企業の財務・戦略的SWOT分析
    Unicharm Corporation (8113) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Takashimaya Company, Limited
    Takashimaya Company, Limited - Strategy, SWOT and Corporate Finance Report Summary Takashimaya Company, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Antares Pharma Inc (ATRS):企業の財務・戦略的SWOT分析
    Antares Pharma Inc (ATRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆